Andrew J. Murphy
Net Worth
Last updated:
What is Andrew J. Murphy net worth?
The estimated net worth of Dr. Andrew J. Murphy is at least $91,829,918 as of 14 Aug 2024. He owns shares worth $30,700,683 as insider, has earned $52,084,685 from insider trading and has received compensation worth at least $9,044,550 in Regeneron Pharmaceuticals, Inc. and Edison International.
What is the salary of Andrew J. Murphy?
Dr. Andrew J. Murphy salary is $1,640,000 per year as Executive Vice President of Research in Regeneron Pharmaceuticals, Inc.. He also receives $844,550 as Senior Vice President of Strategy & Corporation Devel. in Edison International.
How old is Andrew J. Murphy?
Dr. Andrew J. Murphy is 67 years old, born in 1958.
What stocks does Andrew J. Murphy currently own?
As insider, Dr. Andrew J. Murphy owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. (REGN) | Executive Vice President of Research | 53,412 | $574.79 | $30,700,683 |
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Andrew J. Murphy insider trading
Regeneron Pharmaceuticals, Inc.
Dr. Andrew J. Murphy has made 112 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 48 units of REGN stock worth $54,861 on 14 Aug 2024.
The largest trade he's ever made was exercising 20,000 units of REGN stock on 13 Nov 2023. As of 14 Aug 2024 he still owns at least 53,412 units of REGN stock.
Regeneron Pharmaceuticals key executives
Regeneron Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Andrew J. Murphy (67) Executive Vice President of Research
- Dr. George D. Yancopoulos (65) Scientific Founder, Pres, Chief Scientific Officer & Director
- Dr. Leonard S. Schleifer (72) Co-Founder, Pres, Chief Executive Officer & Executive Director
- Mr. Daniel P. Van Plew (52) Executive Vice President and GM of Industrial Operations & Product Supply
- Mr. Robert E. Landry Jr. (61) Executive Vice President of Fin. & Chief Financial Officer